Research ArticleRadiobiology/Dosimetry
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
Johan Blakkisrud, Jon Erik Holtedahl, Ayca Løndalen, Jostein Dahle, Tore Bach-Gansmo, Harald Holte, Stine Nygaard, Arne Kolstad and Caroline Stokke
Journal of Nuclear Medicine April 2018, 59 (4) 704-710; DOI: https://doi.org/10.2967/jnumed.117.195347
Johan Blakkisrud
1Department of Diagnostic Physics, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway, and University of Oslo, Oslo, Norway
Jon Erik Holtedahl
1Department of Diagnostic Physics, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway, and University of Oslo, Oslo, Norway
2Siemens Healthineers, Oslo, Norway
Ayca Løndalen
3Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway
Jostein Dahle
4Nordic Nanovector ASA, Oslo, Norway
Tore Bach-Gansmo
3Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway
Harald Holte
5Department of Oncology, Radiumhospitalet, Oslo University Hospital, Oslo, Norway; and
Stine Nygaard
5Department of Oncology, Radiumhospitalet, Oslo University Hospital, Oslo, Norway; and
Arne Kolstad
5Department of Oncology, Radiumhospitalet, Oslo University Hospital, Oslo, Norway; and
Caroline Stokke
1Department of Diagnostic Physics, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway, and University of Oslo, Oslo, Norway
6Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, Norway
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 4
April 1, 2018
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
Johan Blakkisrud, Jon Erik Holtedahl, Ayca Løndalen, Jostein Dahle, Tore Bach-Gansmo, Harald Holte, Stine Nygaard, Arne Kolstad, Caroline Stokke
Journal of Nuclear Medicine Apr 2018, 59 (4) 704-710; DOI: 10.2967/jnumed.117.195347
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
Johan Blakkisrud, Jon Erik Holtedahl, Ayca Løndalen, Jostein Dahle, Tore Bach-Gansmo, Harald Holte, Stine Nygaard, Arne Kolstad, Caroline Stokke
Journal of Nuclear Medicine Apr 2018, 59 (4) 704-710; DOI: 10.2967/jnumed.117.195347